Med by Cell Press

Online Now: Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study http://dlvr.it/TH5Xkb

The #Technophage team is excited to kick off the new year by sharing our latest publication in Med by Cell Press! Our Phase I/IIa study results for TP-102, an innovative bacteriophage cocktail targeting infected diabetic foot ulcers, demonstrate promising outcomes. The randomized trial confirmed that TP-102 is safe and well-tolerated, with no adverse events reported. It reduced bacterial load in infected ulcers and showed encouraging signs of wound healing in treated patients. While further research is needed - Phase IIb is already underway - this work underscores the potential of bacteriophage therapy as a groundbreaking alternative for managing diabetic foot infections. Tonight, raise your glass to advancing phage therapy in 2025 and beyond! For more details about the paper, please click the link below. #TP102 #diabeticfootinfection #bacteriophage #phagetherapy #clinicaltrial

Latest in Med by Cell Press: Long-term efficacy and safety of vosoritide, the only approved medication for children with achondroplasia, over a duration of up to six years https://lnkd.in/enywqShN In 119 children, vosoritide resulted in a significant height gain of 5.75 cm compared to untreated children after three years and improved body proportionality in younger patients. The treatment was well tolerated, with no new safety concerns identified, indicating that vosoritide effectively promotes growth and enhances quality of life for children with this genetic disorder. Ravi Savarirayan ∙ Melita Irving ∙ William Wilcox ∙ Carlos A. Bacino ∙ Julie Hoover-Fong ∙ Paul Harmatz ∙ Lynda Polgreen ∙ Katja Palm ∙ Carlos Prada ∙ Takuo Kubota ∙ Paul Arundel ∙ Yumiko Kotani ∙ Antonio Leiva Gea (MD, PhD)∙ Michael B. Bober, MD, PhD ∙ Jacqueline T. Hecht ∙ Janet Legare ∙ Sue Lawrinson ∙ Andrea Low ∙ Ian Sabir ∙ Alice Huntsman-Labed ∙ Jonathan Day MBBS PhD Murdoch Children's Research Institute (MCRI) Guy's and St Thomas' NHS Foundation Trust Emory University School of Medicine Baylor College of Medicine The Johns Hopkins University School of Medicine UCSF Benioff Children's Hospitals The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Otto-von-Guericke-Universität Medizinische Fakultät Universitätsklinikum Magdeburg A.ö.R. Ann & Robert H. Lurie Children's Hospital of Chicago Osaka University Sheffield Children's NHS Foundation Trust Tokushima University Instituto de Investigación Biomédica de Málaga Nemours-Alfred I. du Pont Hospital for Children McGovern Medical School The University of Texas Health Science Center at Houston (UTHealth Houston) University of Wisconsin-Madison School of Medicine and Public Health BIOMARIN (U.K.) LTD. #Achondroplasia #Vosoritide #PediatricHealth #GeneticDisorders #BoneGrowth #ClinicalTrials #LongTermCare

New randomized trial in Med by Cell Press explored the safety and efficacy of TP-102, a bacteriophage mixture, for treating diabetic foot ulcers in patients with and without infections https://lnkd.in/eG2kRudB The trial found that TP-102 was well tolerated, with no adverse events reported, and it successfully reduced bacteria in infected ulcers. While the study was not large enough to definitively prove TP-102’s superiority over placebo, a higher percentage of patients treated with TP-102 showed significant wound healing compared to those receiving a placebo. These findings suggest that bacteriophage therapy could be a promising alternative for managing diabetic foot infections, warranting a further larger trial. Ran Nir-Paz ∙ Hadil Onallah ∙ Michal Dekel ∙ Yechiel Gellman ∙ Amir Haze ∙ Ronen Ben-Ami ∙ Ron Braunstein ∙ Ronen Hazan ∙ Danna Dror ∙ Yonatan Oster ∙ Meir Cherniak ∙ Fabienne Attal ∙ Ana Raquel Barbosa ∙ Helena Dordio ∙ Alexandra Wagner ∙ Daniela Jones Dias ∙ José Neves ∙ Margarida Barreto ∙ Clara Leandro ∙ Sofia Corte-Real ∙ Miguel Garcia Hebrew University of Jerusalem - Hadassah Tel Aviv Sourasky Medical Center Tel Aviv University The Hebrew University of Jerusalem TechnoPhage, SA #Diabetes #FootHealth #Bacteriophage #PhageTherapy #DiabeticFootUlcers #WoundHealing #InfectionControl #ClinicalTrials #TP102

Online Now: Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers http://dlvr.it/TH4YTY

Online Now: Regulatory T cell therapy is associated with distinct immune regulatory lymphocytic infiltrates in kidney transplants http://dlvr.it/TH30hn

New treatment strategy for advanced HR+/HER2− breast cancer in patients who had not responded to standard CDK4/6 inhibitors https://lnkd.in/ebQ3YmtA Preclinical studies indicated that combining hydroxychloroquine, an autophagy inhibitor, with a high-dose CDK4/6 inhibitor (palbociclib) could enhance anti-tumor effects while minimizing toxicity. In a phase 1b/2 clinical trial involving 29 patients, this combination demonstrated promising efficacy with a 41.4% objective response rate and manageable side effects, suggesting it could be a viable option for patients who have developed resistance to first-line therapies. Sun Yat-sen University #BreastCancer #HRPositive #HER2Negative #CDKInhibitors #Hydroxychloroquine #CancerResearch #ClinicalTrials #Oncology

Online Now: Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2− breast cancer: A phase 1b/2 trial http://dlvr.it/TH29tf

Excellent long-term kidney function over 7 years without rejection episodes in renal transplant patients receiving Treg therapy https://lnkd.in/eAEdaa4V Kidney transplantation is the preferred treatment for end-stage renal disease, but it typically necessitates lifelong immunosuppression, which can have significant side effects. Treg therapy aims at reducing this reliance on conventional immunosuppression. These patients exhibited immune cell infiltrates enriched with regulatory genes and B cells within the graft, suggesting that local immunoregulation may enhance the effectiveness of Treg therapy. The findings indicate that Treg therapy could facilitate beneficial immune interactions in transplanted kidneys, marking a significant advancement in transplant immunology. Oliver McCallion ∙ Amy R. Cross ∙ Matthew O. Brook ∙ Conor Hennessy ∙ Ricardo Chaves Ferreira ∙ Dominik Trzupek ∙ William R. Mulley ∙ Sandeep Kumar ∙ Maria Fernanda Soares ∙ Ian Roberts ∙ Peter J. Friend ∙ Giovanna Lombardi ∙ Kathryn J. Wood ∙ Paul Harden ∙ Joanna Hester ∙ Fadi Issa Nuffield Department of Surgical Sciences - University of Oxford Oxford University Hospitals NHS Foundation Trust Monash Medical Centre, Monash University Guy's and St Thomas' NHS Foundation Trust King's College London #KidneyTransplant #TregTherapy #Immunosuppression #Transplantation #LongTermOutcomes

Online Now: Molecular insights into trauma: A framework of epigenetic pathways to resilience through intervention http://dlvr.it/TGxl8q